Review: Homocysteine,endothelial dysfunction and oxidative stress in type 1 diabetes mellitus

Abstract

Type 1 diabetes is associated with an increased risk of cardiovascular disease, which cannot be fully explained by traditional risk factors. Elevated plasma homocysteine is an independent risk factor for macrovascular disease in the general population. This review examines the evidence for hyperhomocysteinaemia in patients with type 1 diabetes and describes the mechanisms that may lead to increased macrovascular susceptibility.

While reports of plasma homocysteine levels in type 1 diabetes are inconsistent, increased plasma homocysteine levels have been found in subgroups of patients with microalbuminuria, nephropathy and macrovascular disease. Although a direct causal relationship between plasma homocysteine and atherosclerosis remains to be proven, potential mechanisms of vascular damage by homocysteine include endothelial dysfunction linked to increased oxidative stress. This could contribute to the association between hyperhomocysteinaemia and macrovascular disease in type 1 diabetes.

Keywords

type 1 diabetes homocysteine oxidative stress cardiovascular disease microalbuminuria endothelium.

Get full access to this article

View all access options for this article.

References

Welch G. , Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-50.

Deckert T. , Poulson J. , Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one . Survival, causes of death and complications. Diabetologia 1978;14:363-77.

Stephenson J. , Kenny S. , Stevens L. , Fuller J. , Lee E. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabet Med 1995;12:149-55.

Vaccaro O. , Perna AF , Mancini FP et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 2000 ;10:297-304.

Chico A. , Perez A. , Cordoba A. et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998;41:684-93.

Hultberg B. , Agardh E. , Andersson A. et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991;51:277-82.

Hofmann MA , Kohl B. , Zumbach MS et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21:841-8.

Wilcken DEL. Novel risk factors for vascular disease: the homocysteine hypothesis of cardiovascular disease. J Cardiovasc Risk 1998;5:217-21.

Powers H. , Moat S. Developments in the measurement of plasma total homocysteine. Opin Clin Nutr Metab Care 2000;3:391-7.

10.

McCully. Vascular pathology of homocysteinaemia: implications for the pathogenesis of arteriosclerosis . Am J Pathol 1969;56:111-28.

11.

Graham I. , Daly L. , Refsum H. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997 ;277:1775-81.

12.

Boushey C. , Beresford S. , Omenn G. , Motulsky A. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. JAMA 1995;274:1049-57.

13.

Kaye J. , Stanton K. , McCann V. , Vasikaran S. Homocysteine, folate, MTHFR genotype and vascular morbidity in diabetic subjects . Clin Sci 2002; 102:631-7.

14.

Targher G. , Bertolini L. , Zenari L. et al. Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes. Diabetes Care 2000;23:524-8.

15.

Neugebauer S. , Tarnow L. , Stehouwer C. et al. Total plasma homocysteine is associated with hypertension in type I diabetic patients. Diabetologia 2002;45:1315-24.

16.

Chiarelli F. , Pomilio M. , Mohn A. et al. Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatr 2000 ;137:386-92.

17.

Wiltshire E. , Thomas DW , Baghurst P. , Couper J. Reduced total plasma homocyst(e)ine in children and adolescents with type 1 diabetes. J Pediatr 2001;138:888-93.

18.

Cotellessa M. , Minniti G. , Cerone R. , Prigione F. , Calevo MG , Lorini R. Low total plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 2001;24:969-71.

19.

Pavia C. , Ferrer I. , Valls C. , Artuch R. , Colome C. , Vilaseca MA Total homocysteine in patients with type 1 diabetes. Diabetes Care 2000;23(1):847.

20.

0. Cronin CC , McPartlin JM , Barry DG , Ferriss JB , Scott JM , Weir DG Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 1998;21:1843-7.

21.

Robillon J. , Canivet B. , Candito M. et al. Type 1 diabetes mellitus and homocyst(e)ine . Diabetes Metab 1994;20:494-6.

22.

Frosst P. , Blom HJ , Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation A in methylenetetrahydrofolate reduccular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-13.

23.

Wald D. , Law M. , Moris J. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis . BMJ 2002;325:1202-06.

24.

Shcherbak N. , Shutsleaya Z. , Sheridina A. , Lairionora V. , Schwartz E. MTHFR gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Mol Genet Metab 1999;68:375-8.

25.

Brattstrom L. , Wilcken DEL.

Homocysteine and cardiovascular disease: cause or effect?

Am J Clin Nutr 2000 ;72:315-23.

26.

Perros P. , Singh R. , Laudlern C. , Frier B. Prevalence of pernicious anaemia in patients with type 1 diabetes and autoimmune thyroid disease. Diabet Med 2000;17:749-51.

27.

Holmes G. Coeliac disease and type 1 diabetes - the case for screening. Diabet Med 2001;18:169-77.

28.

Wollesen F. , Brattstrom L. , Refsum H. , Ueland PM , Berglund L. , Berne C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus . Kidney Int 1999;55:1028-35.

29.

Jacques P. , Kalmbach R. , Bagley P. et al. The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. J Nutr 2002;132:283-8.

30.

Miller J. , Ribaya-Mercado J. , Russell R. et al. Effect of vitamin B-6 deficiency on fasting plasma homocysteine concentrations. Am J Clin Nutr 1992; 55:1154-60.

31.

Herrmann W. The importance of hyperhomocysteinemia as a risk factor for diseases: an overview. Clin Chem Lab Med 2001;39:666-74.

32.

Hultberg B. , Agardh CD , Agardh E. , Lovestam-Adrian M. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five-year follow-up study. Scand J Clin Lab Invest 1997 ; 57:595-600.

33.

Bostom A. , Brosnan J. , Hall B. , Nadeau M. , Selhub J. Net uptake of plasma homocysteine by the rat kidney in vivo. Atherosclerosis 1995;116:59-62.

34.

Agardh CD , Agardh E. , Andersson A. , Hultberg B. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1994;54:637-41.

35.

Rossing P. , Astrup A. , Smidt U. , Parving H. Monitoring kidney function in diabetic nephropathy. Diabetologia 1994;37:708-12.

36.

Agardh E. , Hultberg B. , Agardh CD Severe retinopathy in type 1 diabetic patients is not related to the level of plasma homocysteine. Scand J Clin Lab Invest 2000;60:169-74.

37.

Moustapha A. , Naso A. , Nahlawi M. et al. Prospective study of hyperhomocysteinaemia as an adverse cardiovascular risk factor in endstage renal disease. Circulation 1998;97:138-41.

38.

Stehouwer C. , Lambert J. , Donker A. , Van Hinsbergh V. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997 ; 34(1):55-68.

39.

Chambers JC , McGregor A. , Jean-Marie J. , Obeid OA , Kooner JS Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999;99:1156-60.

40.

Chambers JC , Obeid OA , Kooner JS Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler Thromb 1999;19:2922-7.

41.

Bellamy MF , McDowell IFW , Ramsey MW , Brownlee M. , Newcombe RG , Lewis MJ Oral folate enhances endothelial function in hyperhomocysteinuric subjects . Eur J Clin Invest 1999;29:659-62.

42.

Collaboration HLT. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998;316:894-8.

43.

Woo K. , Chook P. , Lolin Y. , Sanderson J. , Metreweli C. , Celermajer D. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia . J Am Coll Cardiol 1999;34:2002-06.

44.

Title L. , Cummings P. , Giddens K. , Genest J. , Nassar B. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000;36:758-65.

45.

Usui M. , Matsuoka H. , Miyazaki H. , Ueda S. , Okuda S. , Imaizumi T. Endothelial dysfunction by acute hyperhomocyst(e)inaemia: restoration by folic acid. Clin Sci 1999;96:235-9.

46.

Doshi S. , McDowell IFW , Moat S. et al. Folate improves endothelial function in coronary artery disease, an effect mediated by reduction of intracellular superoxide? Arterioscler Thromb Vasc Biol 2001;21:1196-202.

47.

Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia . J Clin Invest 1996;98(1):5-7.

48.

Heinecke J. , Rosen H. , Suzuki L. , Chait A. The role of sulphur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987;262: 10098-103.

49.

Jones B. , Rose F. , Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 1994;105:165-70.

50.

Upchurch G. , Welch G. , Fabian A. et al. Homocyst(e)ine decreases bioavailable nitirc oxide by a mechanism involving glutathione peroxidase . J Biol Chem 1997;272:17012-17.

51.

Moat S. , Bonham J. , Cragg R. , Powers H. Elevated plasma homocysteine elicits an increase in antioxidant enzyme activity . Free Rad Res 2000; 32:171-9.

52.

Rabini R. , Staffolani R. , Fumelli P. , Mutus B. , Curatola G. , Mazzanti L. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia 1998;41:101-04.

53.

Mutus B. , Rabini RA , Staffolani R. et al. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects W .Diabetologia 2001;44:979-82.

54.

Kanani P. , Sinkey C. , Browning R. , Allaman M. , Knapp H. , Haynes W. Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocys D t(e)inemia in humans. Circulation 1991;199:1161-8.

55.

Nappo F. , De Rossa N. , Marfella R. et al. Impairment of endothelial function by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281:2113-18.

56.

Bonham J. , Moat S. , Bones C. , McDowell I. , Lewis M. , Powers H. Oral ascorbic acid ameliorates homocysteine-mediated endothelial dysfunction in classical homocysteinuria both acutely and chronically. J Inher Metab Dis 2000;23(suppl):65.